1 on six continents . These trends are critically important for global health, since drug-resistant TB mortality rates are high and second and third-line agents for the treatment of drugresistant TB are less potent and less tolerable than rst-line therapies.
Drug resistance in tuberculosis is a global problem and India is no exception to this This study was taken up to determine the adverse drug reactions prole of a patient, previous history of anti tubercular drug intake and pattern of drug resistant. Globally, 5% of TB cases were estimated to have had MDR-TB in 2013 (3.5% of new and 20.5% of previously treated TB cases). Drug resistance surveillance data show that an estimated 480,000 people developed MDR-TB in 2013 and 210,000 people died. Extensively drug-resistant TB (XDR-TB) has been reported by 100 countries in 2013. On average, an 2 estimated 9% of people with MDR-TB have XDR-TB .
In India, the prevalence of multi-drug resistant TB (MDR-TB), dened as resistance to Isoniazid and Rifampicin with or without resistance to other drugs, is found to be at a low level in most of the regions. Data from several studies conducted by TRC and NTI, have found MDR-TB levels of less than 1% to 3% 3, 4 in new cases and around 12% in re-treatment cases India may be considered as one of the global epicentre of TB including the drug resistant one and many patients are being treated with second line anti-TB drugs. However, there is limited data of adverse drug reactions from the second line anti-TB drugs on the Indian patients. Indian patients are different from their global counterparts both by genetic structure and phenotype; hence prone to differ in anti TB drug action and pharmacokinetics also. Therefore, there is need for more data from the Indian patients related to second line anti-TB drugs including the adverse drug reaction. Hence, the present study was been planned to systemically generate and analyze the adverse drug reaction data of the second line anti TB drugs on Eastern Indian patients.
METHODS
This cross sectional study was designed to include all patients receiving treatment for Drug Resistant TB over a period of one year. So there was no prespecied sample size for this study. This study was conducted at DR-TB centre, Burdwan Medical College and Hospital. Permission of Institutional Ethics Committee was obtained for the study. Written informed consents were obtained from all participating patients. 75 patients were included in the study. They were followed every nd month for 6 (9) months in intensive phase after the start of 2 line drugs and adverse drug reactions were recorded, as the maximum adverse reactions usually occur in this period. Treatment was given as per guidelines by Revised National TB Control Program PMDT (Programmatic management of drug- After selection of each patient on the basis of inclusion and exclusion criteria a written informed consent was taken. Data was collected using a pretested pro forma meeting the objectives of the study. Detailed history, physical examination and necessary investigations were undertaken. The purpose of the study was explained to the patient and informed consent obtained.
A STUDY ON LIVER FUNCTION TEST PROFILE OF 2ND LINE DRUGS IN MULTI DRUG RESISTANT (MDR) AND EXTENSIVELY DRUG RESISTANT (XDR) TUBERCULOSIS CASES REGISTERED UNDER DR-TB CENTRE IN A TERTIARY CARE HOSPITAL
At the end of the study the data was complied, tabulated for analysis.
All the collected data were analysed by using SPSS version 16 statistical software. Descriptive statistics were applied to the data. All data were presented as number and percent. Chi Square Test and Fisher exact test were applied wherever applicable to nd out statistical differences and p value <0.05 were considered statistically signicant.
RESULTS
In our study among the 76 cases, most of them were pulmonary Tuberculosis (96%) whereas only 4% were Extra Pulmonary Tuberculosis. Majority were from age group 21-30 (44%), that is, the most productive age group of life. Majority 64% either th studied upto 5 standard or are illiterate (Fig 1) . 
Figure 1. Distribution of Age Group in MDR and XDR TB Patients
Adverse drug reactions related to Gastro intestinal system like nausea, vomiting, heart burn and sulphurous belching were noted in most of the patients and these were more common after initiation of treatment (Fig 2) . Among the GI related symptoms, incidences of emesis (nausea & vomiting) were higher than even cumulative of all other GI related ADRs and the difference was statistically signicant (p, <0.0001). 
Figure 2: Gastrointestinal System related ADRs

DISCUSSION
The present study has found that the second line anti-TB drugs are prone to produce adverse drug reactions in almost every patient. There was clustering of Gastrointestinal ADRs in the initial phases of treatment. However, in the later phase many patients suffered from neurological ADR. There were also reports of involvement of eye, liver, kidney, heart or skin in a number of patients.
Most of the patients in the present study had suffered from Gastro Intestinal related ADRs. This is corroborated with the Most of the patients had rise in serum ALP whereas only 3.9% had rise in serum SGPT and 22% had raised SGOT. Drugs were stopped or withdrawn in a number of patients. There are several possible explanations for the differences in the number of patients requiring drugs to be removed from the regimen due to ADRs. These include genetic and phenotypic differences of the patients of Eastern India as well as variation in ability of the health care workers to detect ADRs and provide management.
The major strength of the study was complete follow up of the patients for a long duration. The study also utilized the standard tools like WHO-Uppsala Monitoring Center tool for causality assessment which is simple and widely used worldwide. However, there were few weaknesses in the study.
These include limited sample size, no formal sample size preestimation and possibility of under-reporting of ADRs. As the patients were assessed periodically, and reports of the symptoms were mostly dependent on the capacity of the patients to recall the ADRs, there remained the chances of recall bias and underreporting of non-serious ADRs.
CONCLUSIONS
Adverse Drug Reactions are common ndings with second line anti TB drugs. Almost all major systems are affected by the ADRs due to these drugs though the large proportion is nonserious and self limiting. Gastrointestinal ADRs usually cluster around the initiation of treatment Patients with low BMI
